A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
Launched by NEURALY, INC. · Nov 4, 2019
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who are diagnosed with Parkinson's disease according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic criteria or Movement Disorder Society Research Criteria
- • Patients with Parkinson's disease according to protocol specified scale assessments
- • DaTscan consistent with diagnosis of Parkinson's Disease
- • Men or women 30 to 80 years of age
- Exclusion Criteria:
- • Diagnosis of secondary or atypical parkinsonism
- • Prior use of dopaminergic treatment or MAO-B inhibitors for more than 28 days
- • Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit
- • Pregnant or planning to become pregnant
- • Metabolic, surgical, psychiatric or laboratory abnormality that would interfere with study compliance or safety in the judgment of the investigator
About Neuraly, Inc.
Neuraly, Inc. is a pioneering biotechnology company focused on developing innovative therapeutic solutions for neurodegenerative diseases. With a commitment to advancing scientific research and improving patient outcomes, Neuraly leverages cutting-edge technologies and a robust pipeline of drug candidates to address unmet medical needs in conditions such as Alzheimer's disease and Parkinson's disease. The company's multidisciplinary team of experts collaborates closely with academic institutions and industry partners to accelerate the translation of groundbreaking discoveries into effective treatments. Through its rigorous clinical trial programs, Neuraly aims to enhance the understanding of neural mechanisms and deliver transformative therapies that can significantly impact the lives of patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Houston, Texas, United States
Durham, North Carolina, United States
Durham, North Carolina, United States
San Francisco, California, United States
Charlottesville, Virginia, United States
Providence, Rhode Island, United States
Boston, Massachusetts, United States
Little Rock, Arkansas, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Birmingham, Alabama, United States
Miami, Florida, United States
Irvine, California, United States
Toronto, Ontario, Canada
Portland, Oregon, United States
Boston, Massachusetts, United States
New Haven, Connecticut, United States
Tampa, Florida, United States
Washington, District Of Columbia, United States
Baltimore, Maryland, United States
Milwaukee, Wisconsin, United States
Raleigh, North Carolina, United States
Jacksonville, Florida, United States
Philadelphia, Pennsylvania, United States
Boca Raton, Florida, United States
Golden Valley, Minnesota, United States
Ann Arbor, Michigan, United States
Gainesville, Florida, United States
Augusta, Georgia, United States
West Bloomfield, Michigan, United States
Cleveland, Ohio, United States
Kirkland, Washington, United States
Columbus, Ohio, United States
Sun City, Arizona, United States
Tulsa, Oklahoma, United States
Denver, Colorado, United States
Farmington Hills, Michigan, United States
Hollywood, Florida, United States
Birmingham, Alabama, United States
West Long Branch, New Jersey, United States
Winston Salem, North Carolina, United States
Ocala, Florida, United States
Decatur, Georgia, United States
Pasadena, California, United States
Englewood, Colorado, United States
Boston, Massachusetts, United States
Toledo, Ohio, United States
New York, New York, United States
Miami, Florida, United States
Phoenix, Arizona, United States
Irvine, California, United States
Scottsdale, Arizona, United States
Scottsdale, Arizona, United States
Los Angeles, California, United States
Los Angeles, California, United States
Sacramento, California, United States
Bradenton, Florida, United States
Winter Park, Florida, United States
Chicago, Illinois, United States
Springfield, Illinois, United States
Baltimore, Maryland, United States
Minneapolis, Minnesota, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Patients applied
Trial Officials
Dan Lee
Study Director
Neuraly, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials